Patient P-02420
Metabolic response 72 at the day-84 endpoint (observed).
Responding: response probability 50%, metabolic response 61 today; biology is not blocking the drug.
No side effect starting: nausea / gi symptoms 18, tolerability burden 21, no drift from the model.
59 of 61 scheduled doses in the last 60 days are biologically confirmed (97%); 2 were logged but show no dose signature. Dose signature: resting HR +4 bpm, HRV −9 ms.
Trajectory is stable relative to similar patients; keep the current content.
- 🍽Keep meals regular; three to four moderate portions spaced through the day
- 🍽Include a cooked vegetable portion with each main meal
- ✓Log the daily check-in; one line is enough
- ✓A 15-minute walk after lunch
- 💊Take the dose at the same time relative to your evening meal
- 💊No additional supplements this week
Adherence is not the problem.
sleep quality falling under 35 while GI rises
P-02420 is on day 111 of META-24 (EC-01, baseline S13): response improving, tolerance deteriorating, GI favorable. Over 14 days response moved +5 and GI -2; discontinuation risk is 13%. The state is in the restoration basin, heading towards restoration.
Biology sets the gain: FUT2 non-secretor, IL6 high-expression variant, Poor metabolizer, Low butyrate capacity, Low microbial diversity; butyrate capacity 29/100, diversity 2.3. Pushing it down: Escherichia coli 21.984% (LPS load) (-34.8), Low butyrate capacity (-27.3), 4 keystone species absent (-20.4). From the daily log: fat +3.9 GI next day, alcohol +3.9 GI next day, ultra-processed +2.8 GI next day, protein -2.7 GI next day.
No action has been tried yet.
No action is indicated now; the trajectory is stable relative to similar patients.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 META-24 started — Baseline state S13
What changed?
Trajectory is tracking the baseline prediction.
- Treatment adherence+5
- Toxicity+5
- Nutritional resilience-4
- Inflammatory activity-3
- GI instability-2
What helped?
No interventions yet.
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards restoration · 77 from the failing basin, 18 from restoration.
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -2.7 next day on high-intake days · n 25
- Keep fat lowGI +3.9 next day on high-intake days · n 23
- Keep alcohol lowGI +3.9 next day on high-intake days · n 15
- Keep ultra-processed lowGI +2.8 next day on high-intake days · n 13
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+3.9detractor · 95%
- Alcohol+3.9detractor · 95%
- Ultra-processed food+2.8detractor · 95%
- Protein-2.7supporter · 95%
- Simple carbohydrates+2.5detractor · 95%
- Insoluble fibre-0.3no signal · 15%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 4 opportunists above range: Escherichia coli, Enterococcus faecium, Streptococcus gallolyticus
- 4 keystone species absent
- Shannon 2.48 (expected ≥ 3)
- 7 resistance genes
- Tissue recycling index 44
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
- HRV
- 61 ms
- Sleep
- 6.8 h
- Steps
- 4,087
- Resting HR
- 67 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.